Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

Because of tumor heterogeneity and the immunosuppressive tumor microenvironment, most
cancer vaccines typically do not elicit robust antitumor immunological responses in clinical …

Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …

Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic;
however, long-term benefit is limited to a subset of patients for select cancer indications. The …

The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged
as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a …

Autoimmune diseases (ADs) are characterized by the production of autoreactive
lymphocytes, immune responses to self-antigens, and inflammation in related tissues and …

Finding effective treatments for cancer remains a challenge. Recent studies have found that
the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

The immune system plays critical roles in both autoimmunity and cancer, diseases at
opposite ends of the immune spectrum. Autoimmunity arises from loss of T cell tolerance …